US SEC Trading Suspension Halt Orders — June 24, 2026

Trading halted on NYSE American; 1-for-60 reverse split announced but no insider buying or positive guidance; stock remains halted until split effectuation on July 6, 2026

Final delisting from Nasdaq; 7 reverse splits to date, all failing to maintain compliance; stockholders' equity of -$35.2M vs. $2.5M minimum; no revenue-generating products post-spinoff

Received bid price non-compliance notice but has 180-day cure period until Dec 15, 2026; no immediate trading halt; may consider reverse split but no insider buying or positive catalyst

Proposed $150M Ignite merger not enough to sway Nasdaq Panel; Panel expressed skepticism about compliance plan; no insider transactions reported to support confidence

Board and majority shareholders authorized reverse split range of 15-to-1 to 85-to-1, indicating flexibility but also desperation; no fractional shares issued

Stock continues to trade under symbol 'DH' during compliance period; potential for reverse split but no timeline or insider buying to signal management conviction [NEUTRAL/BEARISH]

Spinoff of Ignite leaves two subsidiaries (Adimune and Pearsanta) with no revenue-generating drugs or devices, indicating zero near-term revenue visibility

Reverse split will not change par value ($0.001), suggesting no fundamental change in capital structure; risk of delisting remains high if post-split price fails

Trading suspended June 25, 2026; no appeal or cure period; stock will be delisted from Nasdaq, likely moving to OTC markets with severe liquidity loss

Stockholders' equity of -$35,174,386 vs. $2,500,000 minimum; negative equity indicates insolvency risk and inability to raise capital

Stock halted on NYSE American until reverse split effectuated; if split fails to raise price above $0.10, delisting is imminent

1-for-60 split is extreme; if post-split price does not sustain above minimum, company faces delisting with no further cure

30 consecutive days below $1.00; if not cured by Dec 15, 2026, faces delisting; no insider buying or positive guidance to support turnaround

7 reverse splits completed, including one on May 18, 2026, yet still non-compliant; pattern suggests structural price decline, not just temporary dip

Post-spinoff, subsidiaries have no revenue-generating drugs or devices; zero revenue makes compliance with listing standards nearly impossible

No guidance, no insider buying, no M&A; reliance on potential reverse split which has failed for peers

No insider buying reported despite extreme undervaluation; suggests management lacks confidence in recovery

180-day compliance window until Dec 15, 2026; if company can boost bid price above $1.00 through operational improvements or buyback, stock could re-rate; no immediate halt

May be eligible for additional 180-day period if conditions met, providing up to 12 months to cure; reduces near-term delisting risk

If 1-for-60 split lifts price significantly, stock could regain compliance and resume trading; extreme risk but potential for short-term pop

No positive catalysts; stock will be delisted; short sellers may target if OTC trading begins

Unlike SRxH and ADTX, DH continues trading normally; investors can monitor for any positive news or insider buying before compliance deadline

Holders entitled to fractional shares will receive one whole share, potentially benefiting small shareholders slightly

If peer companies like SRxH and ADTX are delisted, DH may be the only remaining small-cap healthcare data play, potentially attracting value investors

2 of 3 companies (SRxH and ADTX) have announced or attempted reverse splits; ADTX's 7 splits all failed to maintain compliance, indicating that reverse splits are not a cure for fundamental business issues

Nasdaq (ADTX) issued final delisting with no cure period, while NYSE American (SRxH) allowed a halt with a reverse split plan; NYSE American appears more lenient, but both exchanges are enforcing minimum bid price rules aggressively

ADTX's subsidiaries have no revenue-generating products; SRxH's business model is unclear; both are at risk of being worthless post-delisting, highlighting the danger of investing in pre-revenue micro-caps

None of the three filings reported any insider buying or selling, suggesting management teams are not signaling confidence through personal investment; this is a red flag for all three

All three companies are in healthcare or health data; sector is seeing a wave of delistings as cash-burn rates exceed capital-raising ability in a high-interest-rate environment

Watch for trading resumption on July 6, 2026; if post-split price stays above $0.10, stock may avoid delisting; monitor volume and price action

Trading suspended June 25, 2026; watch for OTC ticker and any potential appeal or bankruptcy filing; stock likely to become worthless

180-day cure period ends Dec 15, 2026; watch for any reverse split announcement, buyback, or operational improvement to boost bid price above $1.00

No insider activity yet; any CEO or CFO purchase of shares would be a strong bullish signal; monitor SEC Form 4 filings

After reverse split, watch for insider buying or selling; if insiders sell post-split, it signals lack of confidence in recovery

Proposed $150M merger may still close despite delisting; watch for updates on merger terms and any new listing on another exchange

Next earnings call may provide guidance on compliance plan; watch for any mention of reverse split or capital raise

After split, company must maintain minimum bid price for 30 consecutive days; monitor daily closing prices